Advancing crystal-based fragment screening: investigation of protein crystal environments for improved screening outcomes
Papain-like protease (PLpro) of SARS-CoV-2 is a vital enzyme involved in viral polyprotein processing and in the suppression of host immune response. Due to its strategic role in viral replication and pathogenesis, PLpro represents a valid yet challenging target for drug development. Fragment-based drug discovery (FBDD) is a powerful strategy employed by the FragMAX facility at MAX IV to identify
